Initial Public Offering

Healthcare
Initial Public Offering

Summary

Baird served as a co- manager on this offering.

About

Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH) recently completed an initial public offering of 10,833,334 shares of common stock at a price of $6.00 per share, generating gross proceeds of approximately $65.0 million. The Company intends to use the net proceeds from the offering to reduce outstanding indebtedness and for working capital and other general corporate purposes.

Founded in 1956, Lantheus is a global leader in developing, manufacturing, selling and distributing innovative diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The Company’s agents are routinely used to diagnose coronary artery disease, congestive heart failure, stroke, peripheral vascular disease and other diseases. Clinicians use Lantheus’ imaging agents and products across a range of imaging modalities, including echocardiography, nuclear imaging and magnetic resonance imaging, or MRI. The Company is headquartered in North Billerica, Massachusetts.

For additional information about this transaction, please contact:

Rob Andrews +1 312-609-5489
Jeff Seaman +1 312-609-4687
Lance Lange +1 414-765-7079
Brian Thomas +1 415-627-3275
Vincenzo di Nicola +44 (0) 20 7667 8532
Healthcare
Initial Public Offering
Date
June 2015
Company
Lantheus Holdings, Inc.
Transaction
M&A
Sectors
Healthcare
Target Location
North America

Share